Protocol Ledger

NCT03729362 · Phase III · COMPLETED

A Study Comparing ATB200/AT2221 With Alglucosidase Alfa/Placebo in Adult Subjects With Late-onset Pompe Disease

Interventional Phase III clinical trial protocol NCT03729362 sponsored by Amicus Therapeutics in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-12-04 Enrollment: 125 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03729362
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)125 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03729362
Protocol FieldVerified Registry Value
NCT IdentifierNCT03729362
Consolidated Lead SponsorAmicus Therapeutics
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment125 participants (ACTUAL)
Registered Start Date2018-12-04
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI